Lupin shares gain after USFDA nod, launch of generic Sugammadex Injection for neuromuscular blockade reversal

Shares of Lupin rose from the day's lows on Friday, July 31, after the company received approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) and launched Sugammadex Injection in the United States.

The company has launched Sugammadex Injection in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial presentations.

Lupin said its product is bioequivalent to Merck's Bridion Injection and is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and paediatric patients aged two years and older undergoing surgery.

The launch follows approval of the company's ANDA by the USFDA, Lupin said in an exchange filing on Friday.

Sugammadex is used to reverse the effects of certain muscle relaxants administered during surgical procedures, helping patients recover muscle function after anaesthesia.

Lupin, headquartered in Mumbai, markets branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across more than 100 markets.

Shares of the company gained following the USFDA approval and were trading at ₹2,426.40 as of 11.51 pm, up 0.2%. The stock has gained more than 15% so far in 2026, and about 26% over the last 12 months.

Also read: Astra Microwave shares hit record high after ₹2,205 crore HAL order for Uttam Radar